Intero Biosystems wants pharmaceutical companies to test candidate drugs on miniature human intestines rather than in animals, TechCrunch reports — a pitch aimed at one of the most entrenched and most criticised practices in drug development.
The approach belongs to the rapidly maturing field of organoids and microphysiological systems: small clusters of human cells grown into structures that mimic the function of an organ. A gut model that absorbs compounds the way a human gut does is valuable for the unglamorous work that comes before human trials — establishing whether a drug survives digestion, whether it crosses into the bloodstream, and how it behaves once it gets there. These are the questions that decide whether a molecule is worth millions in further testing or is quietly abandoned.
The regulatory tailwind is real. Regulators on both sides of the Atlantic have been steadily pushing to reduce reliance on animal testing, and legislation in the United States has encouraged alternative methods to be accepted. But acceptance carries its own burden. A replacement model must be predictive, reproducible and standardised, because a test that produces a different answer in two laboratories is not a replacement for anything.
That is both the commercial opening and the difficulty. Animal models are imperfect, slow and ethically fraught, and they retain one enormous advantage: decades of accumulated validation that regulators already know how to interpret. A challenger does not only have to be better science. It has to generate results that drugmakers are willing to act on and that regulators are willing to sign.
